Teriparatide is also known by its brand names, including Forteo and Forsteo [1].
What is Teriparatide used for?
Teriparatide is a form of parathyroid hormone used to treat osteoporosis in postmenopausal women and men at high risk for fracture. It is also used to treat osteoporosis in men and women with low bone mass who are at a high risk for fracture and cannot take other available osteoporosis therapies [1].
How does Teriparatide work?
Teriparatide is a synthetic form of parathyroid hormone that works by stimulating osteoblasts, the cells responsible for building new bone. It increases bone formation and improves bone mineral density, thereby reducing the risk of fractures [2].
When does Teriparatide's patent expire?
Patent information for specific drugs can vary. For detailed information on Teriparatide's patent expiry dates and related exclusivity periods, resources like DrugPatentWatch.com can be consulted [3].
Who manufactures Teriparatide?
The primary manufacturer of Teriparatide under the brand name Forteo is Eli Lilly and Company [1].
What are the risks and side effects of Teriparatide?
Common side effects of Teriparatide include nausea, headache, dizziness, leg cramps, and pain. More serious potential side effects include an increased risk of osteosarcoma, a type of bone cancer, which has been observed in animal studies. It is generally not recommended for patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, or those with a history of bone cancer or radiation therapy to the skeleton [1].
Can biosimilars of Teriparatide be developed?
The development of biosimilars for biologic drugs like Teriparatide is subject to regulatory approval. Once patents and exclusivities expire, companies may seek to market biosimilar versions, offering potentially lower-cost alternatives. Information on approved biosimilars and their availability can be found through regulatory agencies and specialized databases [3].
How does Teriparatide compare to other osteoporosis treatments?
Teriparatide is a bone-anabolic agent, meaning it actively builds new bone, unlike many other osteoporosis treatments that primarily work by slowing bone loss. This anabolic effect can lead to significant increases in bone density. However, it is typically reserved for patients with severe osteoporosis or those who have not responded to other therapies due to its administration method (daily injection) and potential side effects [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/teriparatide
[2] https://www.drugpatentwatch.com/mechanism-of-action/teriparatide
[3] https://www.drugpatentwatch.com/